MedTrace Logo

Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis

NCT01905423 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17108

Last updated 2020-11-17

Study results available
· View outcomes & findings →

Summary

Approximately 3,500 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis endemic areas. The study will be performed in Indonesia in B. timori and W. bancrofti endemic areas over a period of 4 years. Participants will be studied only once in cross-sectional surveys. Some subjects may be included in more than one annual population survey, but this is not a longitudinal study. Purpose of the study is to evaluate different mass drug administration (MDA) regimens for lymphatic filariasis and also to study the impact of MDA on soil transmitted helminth infections (STH). MDA will administered by others (e.g., Ministry of Health). Results of this study may enhance efforts to control and eliminate these important neglected tropical diseases.

The investigators will test the hypothesis that accelerated mass drug administration will be superior to annual MDA for elimination of lymphatic filariasis and for control of soil transmitted helminth infections (STH):

1. Compare the relative impact and cost effectiveness of annual vs. twice yearly mass drug administration (MDA) for elimination of lymphatic filariasis (LF).
2. Study the impact of annual vs. semiannual MDA on soil transmitted helminth (STH) infection in these populations.

Conditions

  • Lymphatic Filariasis
  • Soil Transmitted Helminth Infections

Interventions

DRUG

Albendazole (annual)

Albendazole 400 mg pnce annually

DRUG

Diethylcarbamazine (annual)

Diethylcarbamazine 6 mg/kg once annually

DRUG

Albendazole (semiannual)

Albendazole 400 mg twice annually

DRUG

Diethylcarbamazine (semiannual)

Diethylcarbamazine 6 mg/kg twice annually

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Peter U Fischer, Ph.D. · Washington University School of Medicine

  • Gary J Weil, MD · Washington University School of Medicine

  • Taniawati Supali, Ph.D. · Indonesia University

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2015-03-31
Completion
2015-12-31

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01905423 on ClinicalTrials.gov